4.7 Meeting Abstract

A randomized phase II study of vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: A New York Cancer Consortium led study

Journal

JOURNAL OF CLINICAL ONCOLOGY
Volume 31, Issue 4, Pages -

Publisher

AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/jco.2013.31.4_suppl.67

Keywords

-

Categories

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available